Scarica l'app Stockscreener
3.56
0.84%
-0.03
Pre-mercato:
3.53
-0.03
-0.84%
Puma Biotechnology Inc Borsa (PBYI) Ultime notizie
Puma Biotechnology Holds Annual Stockholders Meeting 2025 - TipRanks
Should Value Investors Buy Puma Biotechnology (PBYI) Stock? - Yahoo Finance
With 57% ownership, Puma Biotechnology, Inc. (NASDAQ:PBYI) boasts of strong institutional backing - Yahoo Finance
Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Sold by Squarepoint Ops LLC - Defense World
78,653 Shares in Puma Biotechnology, Inc. (NASDAQ:PBYI) Purchased by Mackenzie Financial Corp - Defense World
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)June 4, 2025 - BioSpace
Puma Biotechnology Awards Key Talent with 18,250 RSUs in Strategic Retention Move - Stock Titan
Why Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for Value Investors - sharewise
Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now? - Yahoo Finance
Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Fly 25% But Investors Aren't Buying For Growth - simplywall.st
Is Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Latest Stock Performance A Reflection Of Its Financial Health? - simplywall.st
Puma Biotechnology Inc (PBYI) Forecast: Revisiting The Past To Gain Insights For The Future - Stocksregister
Puma Biotechnology's (NASDAQ:PBYI) Earnings Are Of Questionable Quality - Yahoo Finance
Puma Biotechnology targets $192M-$198M NERLYNX revenue for 2025 amid strategic efforts - MSN
Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Bought by Wells Fargo & Company MN - Defense World
Despite Fast-paced Momentum, Puma Biotech (PBYI) Is Still a Bargain Stock - Nasdaq
PBYI Stock Rises as Q1 Earnings and Sales Beat Estimates - MSN
Puma Biotechnology First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q1 2025 Earnings Call Transcript - Insider Monkey
Puma Biotech CCO Jeff Ludwig departs, no replacement named By Investing.com - Investing.com Canada
Puma Biotech CCO Jeff Ludwig departs, no replacement named - Investing.com
Puma Biotechnology, Inc. Announces Termination of Jeff J. Ludwig as Chief Commercial Officer - marketscreener.com
Is Puma Biotechnology (PBYI) Stock Undervalued Right Now? - Yahoo Finance
Puma Biotechnology Terminates Chief Commercial Officer - TipRanks
Puma Biotechnology Inc (PBYI) Q1 2025 Earnings Call Highlights: Revenue Growth Amidst Challenges By GuruFocus - Investing.com Canada
Puma Biotechnology Reports Positive Q1 2025 Earnings - TipRanks
Puma Biotech Q1 2025 slides: NERLYNX revenue up 7% YoY despite quarterly decline - Investing.com Canada
Puma Biotech: Q1 Earnings Snapshot - The Washington Post
Cautious Hold Rating on Puma Biotechnology Amid Declining Sales and Uncertain Trial Outcomes - TipRanks
Earnings call transcript: Puma Biotech Q1 2025 results miss forecasts By Investing.com - Investing.com UK
Puma Biotechnology Reports First Quarter Financial Results - BioSpace
Puma Biotech (PBYI) Q1 Earnings and Revenues Top Estimates - Yahoo Finance
Earnings call transcript: Puma Biotech Q1 2025 results miss forecasts - Investing.com
Check out these key findings about Puma Biotechnology Inc (PBYI) - Sete News
Puma Biotech (PBYI) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
Er-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX® (neratinib) for Breast Cancer Patients - The Manila Times
Er-Kim Announces Exclusive Distribution Agreement with Puma - GlobeNewswire
Puma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025 - Yahoo Finance
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):